Apart from molecular targets expressed in cancer cells of the three types of programs, CD52, CDK6, HDAC2, and PIGF were specifically expressed in inflammatory or EMT meta programs, indicating that drugs against these targets may respond in specific cancer cell subpopulations. This evidence concerns the gene CD52 and cancer.